Program
resomelagon acetate
Also written as “AP1189, 100 mg”, “100 mg AP1189” and “AP1189, 40 mg”.
Its studies are mostly in Arthritis, Rheumatoid · Influenza, Human · Glomerulonephritis, Membranous, led by SynAct Pharma Aps.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SynAct Pharma Aps | 63 open or running | phase 2since Jun 26, 2019 | Jun 26, 2019 | Aug 1, 2027phase 2 · NCT07633288 |
Also a collaborator on its studies: nbcd-a-s.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2019First study: phase 2 study in Arthritis, RheumatoidFirst studyNCT04004429 · 105 enrolled · Denmark, Norway
- Jun 24, 2020Phase 2 study in Nephrotic Syndrome Due to Idiopathic Membranous NephropathyNCT04456816 · 23 planned · Denmark
- Aug 24, 2022Phase 2 study in Arthritis, RheumatoidNCT05516979 · 127 enrolled · Moldova, Republic of
- Oct 31, 2022Phase 2 study in Arthritis, RheumatoidNCT05604885 · 125 enrolled · Moldova, Republic of
- Oct 31, 2024Phase 2 study in Arthritis, RheumatoidNCT06671054 · 240 planned · United States, Bulgaria, Denmark and more
- Jun 2, 2026Phase 2 study in Influenza, HumanNCT07633288 · 96 planned · Bosnia and Herzegovina, Montenegro, New Zealand and more
Ahead
- Aug 1, 2027Primary completion: phase 2 study in Influenza, HumanNCT07633288
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633288Influenza, Human · Bosnia and Herzegovina, Montenegro, New Zealand and more | 2 | Recruiting | Aug 1, 2027 | 96 |
| NCT06671054Arthritis, Rheumatoid · United States, Bulgaria, Denmark and more | 2 | Recruiting | Dec 2025 | 240 |
| NCT05604885Arthritis, Rheumatoid · Moldova, Republic of | 2 | Completed | Aug 28, 2023 | 125 |
| NCT05516979Arthritis, Rheumatoid · Moldova, Republic of | 2 | Completed | Jul 20, 2023 | 127 |
| NCT04456816Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy · Denmark | 2 | Recruiting | Jun 30, 2026 | 23 |
| NCT04004429Arthritis, Rheumatoid · Denmark, Norway | 2 | Completed | Nov 16, 2021 | 105 |
How it is read
Names in the registry
- “AP1189, 100 mg”, 3 entries
- “100 mg AP1189”, 2 entries
- “AP1189, 40 mg”, 1 entry
- “AP1189, 70 mg”, 1 entry
- “AP1189, 60 mg”, 1 entry
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 4 studies
- Influenza, Human, 1 study
- Glomerulonephritis, Membranous, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.